The present invention relates to a novel immunity inducing agent for treating and/or preventing cancer. More specifically, the present invention relates to: an immunity inducing agent that comprises as an active ingredient at least one polypeptide, said polypeptide being selected from among MRAP2-derived polypeptides and variants thereof and having an immunity induction activity, or a recombinant vector, said recombinant vector containing a polynucleotide encoding the polypeptide and being capable of expressing the polypeptide in a living organism； and an immunity induction method that comprises administering the immunity inducing agent to a subject.
